1 Min Read
* PHASE 2 STUDY OF PR013, TOPICAL OPHTHALMIC SOLUTION FOR TREATMENT OF ALLERGIC CONJUNCTIVITIS, DID NOT DEMONSTRATE EFFICACY
* REALM HAS DECIDED TO DISCONTINUE FURTHER DEVELOPMENT OF THIS PROGRAM Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.